A Routine Blood Test May Help Identify People at Risk for Deadly Infection After Spleen Loss

USU study finds low levels of a key antibody may flag service members, veterans, and others at risk of deadly infection after spleen loss.

U.S. Air Force Staff Sgt. Maribella Gonzalez Ortiz, wearing a camouflage uniform and gray gloves, draws blood from a patient’s arm into a collection tube during a clinic visit.
U.S. Air Force Staff Sgt. Maribella Gonzalez Ortiz, a health services technician with the 125th Medical Group, draws blood during a routine clinic visit at Jacksonville Air National Guard Base, Florida, Feb. 12, 2025. A study led by Uniformed Services University researchers found that a common blood test for the antibody immunoglobulin M (IgM) may help identify people at risk of a deadly infection after spleen loss. (U.S. Air National Guard photo by Senior Airman Brooke Keisler)

November 18, 2026 submitted to USU News by Wendy Li

For anyone who has lost a spleen, including service members injured in combat, the danger of a life-threatening infection doesn’t necessarily end after recovery from surgery. It can last for decades, even after recommended vaccinations. Now, researchers at the Uniformed Services University of the Health Sciences (USU) have identified a potential way to help doctors recognize who may be most vulnerable: a simple blood test that measures a key antibody.

In a national study of nearly 3,000 Military Health System patients without a functioning spleen, researchers found that low levels of immunoglobulin M (IgM), an antibody that helps the body fight bacterial infections, were strongly associated with a severe and potentially fatal infection known as overwhelming post-splenectomy infection (OPSI). The findings, published in The Journal of Allergy and Clinical Immunology: In Practice, suggest that an inexpensive, widely available blood test could help identify patients who need closer monitoring and preventive care. 

The spleen helps protect the body by clearing certain bacteria from the bloodstream. People who have had a splenectomy, the surgical removal of the spleen, and people whose spleen no longer works properly face an increased risk of serious infection for the rest of their lives. Doctors call either condition asplenia. OPSI is uncommon, but it can progress rapidly and prove fatal.

Vaccines and preventive antibiotics are the standard defenses, but severe infections still break through, in part because of gaps in clinical awareness and underlying weakness in the immune system. The problem carries particular weight for service members who lose their spleens after combat injuries or other serious trauma. Their risk does not end when they leave military service; it can follow them into retirement and the Department of Veterans Affairs (VA) health care system.

Three dot plots compare blood levels of the antibodies IgG, IgA, and IgM in patients with asplenia who did and did not develop OPSI. IgG levels are similar between the two groups, IgA levels are slightly lower in the OPSI group, and IgM levels are far lower in the OPSI group, with most OPSI patients below 100 milligrams per deciliter.
Blood levels of three antibodies in patients without a working spleen, grouped by whether they developed overwhelming post-splenectomy infection (OPSI). Immunoglobulin M (IgM), right, was far lower in patients who developed OPSI, while immunoglobulin G (IgG), left, showed no meaningful difference and immunoglobulin A (IgA), center, was slightly lower. (Figure courtesy of The Journal of Allergy and Clinical Immunology: In Practice)

First author U.S. Navy Lt. Cmdr. (Dr.) W. Grant Day and senior author U.S. Army Maj. (Dr.) Jeremy C. McMurray, both assistant professors of Medicine at USU, led the research team. Their collaborators included USU Department of Medicine colleagues Dr. Luke M. Pittman and Dr. Nathan A. Boggs, along with researchers from military hospitals, the Defense Health Agency, and the National Institutes of Health. 

Day also practices in the Allergy and Immunology Service at Naval Medical Center Portsmouth, and McMurray at Walter Reed National Military Medical Center. The team analyzed health records for 2,992 TRICARE beneficiaries with asplenia and identified 47 cases of OPSI. TRICARE is the military health care program for service members, retirees, and their families.

The study, titled “A Link Between Immunoglobulin M Levels and Overwhelming Postsplenectomy Infection Risk in a National Asplenia Cohort,” was published online ahead of print Oct. 23. Co-authors also include Dr. Brandon J. Schornack of Walter Reed National Military Medical Center, Dr. Matthew A. Soderstrom of Brooke Army Medical Center, Janet A. Brunader and Agustin Moreno of the Defense Health Agency, and Dr. V. Koneti Rao of the National Institutes of Health.

An IgM level below 61.5 milligrams per deciliter appeared in nearly 87% of patients who developed the infection, compared with 15% of those who did not. After accounting for other factors, researchers found that patients with low IgM had about 26 times higher odds of developing OPSI.

At that threshold, the test identified about 87% of patients who developed OPSI and correctly identified 85% of those who did not. On a standard measure of diagnostic accuracy, where 0.5 represents a coin flip and 1.0 represents perfect accuracy, IgM levels scored 0.92.

Most patients who developed OPSI had records showing they had received vaccines intended to protect against the same bacteria that caused their infections. Streptococcus pneumoniae, a bacterium commonly associated with pneumonia, caused 89% of the infections in the study.

Vaccination remains essential for people without a functioning spleen, but the findings suggest that vaccination history alone may not capture a patient’s individual risk. Measuring IgM levels could provide another way to identify patients who need additional monitoring and preventive care.

Flowchart of a proposed screening approach for patients with asplenia who have not had OPSI. Clinicians confirm vaccinations against Hib, MenACWY, MenB, PCV13, PCV15, PCV20, and PPSV23, then order a serum IgM test. If IgM is below 61.5 milligrams per deciliter (86.7% sensitivity, 85.0% specificity), the next step is close follow-up, a comprehensive immune evaluation, and a prescription for emergency antibiotics. If not, patient and clinician decide on follow-up together.
A screening framework from the study for people without a working spleen who have not had overwhelming post-splenectomy infection (OPSI). After confirming vaccinations, clinicians would order an immunoglobulin M (IgM) blood test, and a level below 61.5 milligrams per deciliter would prompt close follow-up, a full immune evaluation, and a prescription for emergency antibiotics. (Figure courtesy of The Journal of Allergy and Clinical Immunology: In Practice)

OPSI occurred in about 1.6% of the patients studied, or roughly 1 in 64, but the infection was often severe and proved fatal even in previously healthy patients. The risk also persisted long after surgery. The median time between spleen removal and infection was 6.5 years, and researchers documented cases occurring as long as 40 years afterward. 

That long timeline shapes how military medicine approaches the risk. A service member who loses a spleen in a combat injury may move from active duty to reserve status and into VA or civilian care over the course of decades. Keeping track of the risk across each of those transitions is part of force health protection, the military’s term for preventing illness and injury across a service member’s career and beyond.

Day said a warning sign that shows up in routine lab work, known as a biomarker, could give military and VA clinicians a practical way to spot patients who need closer attention, even decades after an injury or surgery. “What makes this finding particularly exciting is that IgM can be measured through a simple, inexpensive blood test that is already widely available,” Day said. “Rather than relying on vaccination history alone, this biomarker could help military and VA clinicians identify patients at greatest risk and guide more personalized, lifelong surveillance and preventive care.”

Previous studies of OPSI risk focused largely on patient characteristics, such as age, the reason for spleen removal, and the time since surgery. This study is the first to identify a potential biomarker for OPSI risk. The authors concluded that low IgM may help identify patients who need closer surveillance and management.

For a sailor who lost a spleen to a blast injury at age 22, that could mean a routine blood test at a VA clinic decades later flags a risk that might otherwise go unnoticed and prompts closer monitoring before a life-threatening infection takes hold.